Beone Medicines has delivered a stellar first-half performance for fiscal 2026, with profitability climbing sharply year-on-year and validating the effectiveness of its commercial strategy.

According to the company's filing, total revenue for the six months ended June 30, 2026, grew 32.3% year-on-year to $3.219 billion. Net profit surged 385.8% to $464 million, reflecting an accelerated release of operating leverage. Diluted earnings per ADS jumped to $4.01, up from $0.85 in the prior-year period.

The primary growth engine was robust demand for the flagship product Brukinsa (zanubrutinib) across the US and European markets. On a non-GAAP basis, net profit reached $820 million, with operating cash flow of $664 million and free cash flow of $596 million. Cash and cash equivalents stood at $5.1 billion as of period-end.

Zanubrutinib Dominates with Dual US-Europe Momentum

Zanubrutinib (Brukinsa) served as the most critical performance driver during the reporting period. Global sales for the first half reached $2.342 billion, up 34.5% year-on-year, accounting for 74% of total product net revenue.

By region, US sales climbed 32.6% to $1.654 billion, supported by demand growth across all approved indications and favorable net pricing, with approximately $20 million attributable to a non-recurring gross-to-net adjustment in the first quarter. The European market delivered standout results, with sales rising 41.9% to $378 million, driven by market share gains across key countries. China sales reached $191 million, up 16.3%, while other regions saw revenue surge 87.3% to $120 million.

The second core product Tevimbra (tislelizumab) generated revenue of $435 million, up 19.2% year-on-year. Products licensed from Amgen collectively contributed $299.5 million in China, with Xgeva growing 28.1% to $194 million, making it the largest contributor among licensed products.

Additionally, other revenue jumped 133.9% to $51.4 million, primarily driven by royalty income from IMDELLTRA under the Amgen collaboration agreement, as well as revenue from the Novartis broad-market agreement.

Gross Margin Expands While Expense Growth Lags Revenue Gains

The profitability surge stems from rapid revenue growth combined with sustained operational efficiency improvements. Product gross margin for the first half rose to 89.2%, up from 86.3% in the prior-year period, mainly due to the higher mix of high-margin zanubrutinib and improved production efficiency for both zanubrutinib and tislelizumab. On a non-GAAP basis, gross margin reached 89.6%.

On the operating expense front, R&D expenses grew 14.6% to $1.154 billion, while selling and administrative expenses rose 15.2% to $1.148 billion. Combined, these two expense lines increased 14.9%, well below the 32.3% revenue growth rate, underscoring significant operating leverage. Selling and administrative expenses as a percentage of product sales declined to 36.3% from 41.4% a year earlier.

Operating profit consequently surged 480.8% to $574.9 million, up from $98.99 million in the prior-year period.

Notably, interest expense increased by $57.6 million to $72.6 million, a 384.3% jump. This was primarily due to $43.4 million in interest expense recognized under the effective interest method on the Royalty Pharma liability arising from the 2025 sale of future IMDELLTRA royalties, along with reduced capitalized interest following the completion of the Hopewell facility.

Pipeline Progress: Multiple Approvals and Strategic Collaborations

During the reporting period and subsequent months, Beone Medicines achieved significant milestones in both R&D and commercialization.

In May 2026, Sonrotoclax (Brukinsa's companion BCL2 inhibitor) received FDA accelerated approval for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy. In August 2026, the FDA approved a new indication for tislelizumab in combination with zanidatamab and chemotherapy as first-line treatment for adult patients with HER2-positive gastroesophageal adenocarcinoma.

Also in August 2026, the company announced a multi-faceted collaboration agreement with Revolution Medicines, encompassing clinical combination evaluations and regional licensing rights granting Beone Medicines exclusive development and commercialization rights for certain Revolution Medicines candidates in select Asian markets.

In July 2026, the company announced an additional $300 million investment to expand its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, adding small-molecule drug production capacity.

In June, the Phase 3 MANGROVE study, evaluating zanubrutinib in combination with rituximab for mantle cell lymphoma, yielded positive results, further strengthening the clinical data foundation for its core product.

Ample Cash Position with One-Time Tax Impact

As of June 30, 2026, the company held $5.098 billion in cash and cash equivalents, with restricted cash totaling $528 million, providing ample liquidity. Total debt stood at $1.073 billion, with the debt-to-capital ratio declining to 20.7% from 23.4% at the end of 2025.

The company expects to repay approximately $201.1 million in bank loans over the next 12 months, with existing cash and operating cash flows fully covering these obligations and operating expenses for the coming year.

Regarding income tax expense, $107.3 million was recognized during the reporting period, a significant year-on-year increase. This included approximately $49.28 million in one-time tax items, primarily related to the settlement of a tax inspection matter involving one of the company's Chinese subsidiaries, with a tax impact of $59.03 million, partially offset by non-recurring tax items related to US equity incentives. Excluding these non-recurring items, the adjusted effective tax rate was 10.3%.

Furthermore, the company holds approximately $3.6 billion in deferred tax assets, which remain subject to a full valuation allowance. The company indicated it may release all or part of the valuation allowance in the near term, though the specific timing and amount depend on factors including profitability levels, revenue growth, and clinical program progress. Should the valuation allowance be released in the future, it would have a material positive impact on net profit.